

Study of Serum Levels of Cyclophilin A in Patients with Coronary Artery Disease

Thesis

*Submitted for Partial Fulfillment of Master Degree in
Clinical Pathology*

By

Rana Mahmoud Sedky
MB BCh –Ain Shams University

Under Supervision of

Professor/ Mona Mohamed Zaki

*Professor of Clinical Pathology
Faculty of Medicine – Ain Shams University*

Doctor/ Manal Mohsen M. Kamal El-Din

*Assistant Professor of Clinical Pathology
Faculty of Medicine – Ain Shams University*

Doctor/ Menat Allah Ali Shaaban

*Assistant Professor of Clinical Pathology
Faculty of Medicine – Ain Shams University*

Faculty of Medicine
Ain Shams University
2019

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قالوا

سبحانك لا علم لنا
إلا ما علمتنا إنك أنت
العليم العظيم

صدق الله العظيم

سورة البقرة الآية: ٣٢

Acknowledgment

*First and foremost, I feel always indebted to **ALLAH**, the Most Kind and Most Merciful.*

*I'd like to express my respectful thanks and profound gratitude to **Professor/ Mona Mohamed Zaki**, Professor of Clinical Pathology, Faculty of Medicine- Ain Shams University for her keen guidance, kind supervision, valuable advice and continuous encouragement, which made the completion of this work possible.*

*I am also delighted to express my deepest gratitude and thanks to **Doctor/ Manal Mohsen M. Kamal El-Din**, Assistant Professor of Clinical Pathology, Faculty of Medicine, Ain Shams University, for her kind care, continuous supervision, valuable instructions, constant help and great assistance throughout this work.*

*I am deeply thankful to **Doctor/ Menat Allah Ali Shaaban**, Assistant Professor of Clinical Pathology, Faculty of Medicine, Ain Shams University, for her great help, active participation and guidance.*

*I would like to express my hearty thanks to all **my family** for their support till this work was completed.*

Rana Mahmoud Sedky

List of Contents

Title	Page No.
List of Tables	i
List of Figures	iii
List of Abbreviations	v
Introduction	1
Aim of the Work.....	11
Review of Literature	
📖 Coronary Artery Disease	12
📖 Cyclophilin A	45
Subjects and Methods	67
Results	83
Discussion	93
Summary	100
Conclusion.....	102
Recommendations	103
References	104
Arabic Summary	

List of Tables

Table No.	Title	Page No.
Table (1):	Spearman's Rank Correlation between CyPA and Other Studied Parameters in the Whole Patient Group	86
Table (2):	Statistical Comparison between the Whole Patient Group and the Control Group Regarding the Different Associated Risk Factors Using Chi-square Test	87
Table (3):	Odd's Ratio for Risk Factors.....	87
Table (4):	Descriptive and Comparative Statistics of the Different Studied Parameters in the Whole Patients' Group and the Control Group using Wilcoxon's Rank Sum Test	88
Table (5):	Descriptive and Comparative Statistics of the Different Studied Parameters in the Different Patient Subgroups	89
Table (6):	Statistical Comparison of Serum Level of CyPA in the Different Studied Sub-groups using Wilcoxon's Rank Sum Test	90
Table (7):	Logistic Multi Regression Analysis Used to Predict the Most Sensitive Predictors of CAD	90
Table (8):	Diagnostic Performance of CyPA as a Risk Factor in CAD Patients' Group versus Control Group	91
Table (9):	Diagnostic Performance of CyPA When Combined with Hypertension as a Risk Factor in CAD Patients' Group versus Control Group....	91
Table (10):	Diagnostic Performance of CyPA in CAD (0 vessel disease) Group versus Control Group	92

List of Tables (Cont...)

Table No.	Title	Page No.
Table (11):	Diagnostic Performance of CyPA When Combined with Hypertension as a Risk Factor in CAD (0 vessel disease) Group versus Control Group	92

List of Figures

Fig. No.	Title	Page No.
Figure (1):	Pathophysiological progression of atherosclerosis	14
Figure (2):	Lesion types of atherosclerosis and sequence of their development	17
Figure (3):	An overview over the effect of physical activity on key factors in the atherosclerotic process.....	24
Figure (4):	Temporal release of myoglobin, CK-MB, cTnI and cTnT	39
Figure (5):	A schematic representation of the complex interplay between dyslipidemia and hypertension in the development of atherosclerosis	51
Figure (6):	Cyp A effect on viruses.....	54
Figure (7):	Steps of western blot assay. SDS: sodium dodecyl sulphate	60
Figure (8):	Phases of PCR amplification curve.	65
Figure (9):	Preparation of Set of Standards Using Standard Dilution.	74
Figure (10):	Box Blot, showing median levels of CyPA (ng/mL) in CAD patients' group and control group.	88
Figure (11):	Receiver Operating Characteristic curve (ROC) analysis showing the diagnostic performance of cyPA and its combination with positive hypertension for discriminating patients with CAD from those control group.....	91

List of Figures (Cont...)

Fig. No.	Title	Page No.
Figure (12):	ROC curve analysis showing the diagnostic performance of CyPA and its combination with positive hypertension for discriminating patients with 0 Vessel disease from those control.	92

List of Abbreviations

Abb.	Full term
<i>ACS</i>	<i>Acute Coronary Syndrome</i>
<i>AMI</i>	<i>Acute Myocardial Infarction</i>
<i>Apo A-1</i>	<i>Apo-Lipoprotein A-1</i>
<i>AUC</i>	<i>Area under Curve</i>
<i>BMI</i>	<i>Body Mass Index</i>
<i>CABG</i>	<i>Coronary Artery Bypass Graft</i>
<i>CD147</i>	<i>Cluster of Differentiation 147</i>
<i>CK</i>	<i>Creatine Kinase</i>
<i>CK-MB</i>	<i>Creatine Kinase MB Fraction</i>
<i>CLD</i>	<i>Cyclophilin-Like Domain</i>
<i>CMIA</i>	<i>Chemiluminescent Microparticle Immunoassay</i>
<i>CMR</i>	<i>Cardiac Magnetic Resonance</i>
<i>CRP</i>	<i>C- Reactive Protein</i>
<i>CsA</i>	<i>Cyclosporine A</i>
<i>CT</i>	<i>Computed Tomography</i>
<i>CTA</i>	<i>Computed Tomography Angiography</i>
<i>CyPA</i>	<i>Cyclophilin A</i>
<i>DALY</i>	<i>Disability Adjusted Life Years</i>
<i>DBP</i>	<i>Diastolic Blood Pressure</i>
<i>DM</i>	<i>Diabetes Mellitus</i>
<i>EC</i>	<i>Endothelial Cells</i>
<i>ECG</i>	<i>Electrocardiography</i>
<i>eCyPA</i>	<i>Extracellular Cyclophilin A</i>
<i>ELISA</i>	<i>Enzyme Linked Immunosorbent Assay</i>
<i>EMG</i>	<i>Exponentially Modified Gaussian</i>
<i>eNOS</i>	<i>Endothelial Nitric Oxide Synthase</i>
<i>EPC</i>	<i>Endothelial Progenitor Cell</i>
<i>ER</i>	<i>Endoplasmic Reticulum</i>
<i>GC-A</i>	<i>Guanylate Cyclase A</i>

List of Abbreviations (Cont...)

Abb.	Full term
<i>HbA_{1c}</i>	<i>Glycated Hemoglobin</i>
<i>HBV</i>	<i>Hepatitis B Virus</i>
<i>HCV</i>	<i>Hepatitis C Virus</i>
<i>HDL-C</i>	<i>High Density Lipoprotein Cholesterol</i>
<i>His</i>	<i>Histidine</i>
<i>HIV</i>	<i>Human Immunodeficiency Virus</i>
<i>HPLC</i>	<i>High Performance Liquid Chromatography</i>
<i>HR</i>	<i>Heart Rate</i>
<i>HRP</i>	<i>Horse Radish Peroxidase</i>
<i>Hs-CRP</i>	<i>High Sensitive C Reactive Protein</i>
<i>ICAM</i>	<i>Intracellular Adhesion Molecule</i>
<i>iCyPA</i>	<i>Intracellular Cyclophilin A</i>
<i>IFN-γ</i>	<i>Interferon γ</i>
<i>IL-1β</i>	<i>Interleukin 1β</i>
<i>IL₆</i>	<i>Interleukin 6</i>
<i>IL-8</i>	<i>Interleukin 8</i>
<i>LDL</i>	<i>Low Density Lipoproteins</i>
<i>LVEF</i>	<i>Left Ventricular Ejection Fraction</i>
<i>Lys</i>	<i>Lysine</i>
<i>M1</i>	<i>Matrix Protein 1</i>
<i>MAPK</i>	<i>Mitogen Activated Protein Kinase</i>
<i>MCP-1</i>	<i>Monocyte Chemoattractant Protein-1</i>
<i>MGB</i>	<i>Minor Groove Binder</i>
<i>MMP-9</i>	<i>Matrix Metalloproteinase-9</i>
<i>NADPH</i>	<i>Reduced Nicotinamide Adenine Dinucleotide Phosphate</i>
<i>NFQ</i>	<i>Nonfluorescent Quencher</i>
<i>NF-κB</i>	<i>Nuclear Factor Kappa B</i>
<i>NO</i>	<i>Nitric Oxide</i>

List of Abbreviations (Cont...)

Abb.	Full term
<i>NPV</i>	<i>Negative Predictive Value</i>
<i>NSTEMI</i>	<i>Non ST Elevation Myocardial Infarction</i>
<i>OD</i>	<i>Optical Density</i>
<i>PCI</i>	<i>Percutaneous Coronary Intervention</i>
<i>PIT</i>	<i>Pathological Intimal Thickening</i>
<i>PPIA</i>	<i>Peptidyl Prolyl Isomerase A</i>
<i>PPV</i>	<i>Positive Predictive Value</i>
<i>RAAS</i>	<i>Renin Angiotensin Aldosterone System</i>
<i>RLUs</i>	<i>Relative Light Units</i>
<i>ROC</i>	<i>Receiver Operating Characteristic Curve</i>
<i>ROS</i>	<i>Reactive Oxygen Species</i>
<i>SAA</i>	<i>Serum Amyloid A</i>
<i>SBP</i>	<i>Systolic Blood Pressure</i>
<i>SDS</i>	<i>Sodium Dodecyl Sulphate</i>
<i>SMC</i>	<i>Smooth Muscle Cell</i>
<i>SOD</i>	<i>Super Oxide Dismutase</i>
<i>STEMI</i>	<i>ST Elevation Myocardial Infarction</i>
<i>TCFA</i>	<i>Thin Cap Fibro Atheroma</i>
<i>TNF-α</i>	<i>Tumour Necrosis Factor – Alpha</i>
<i>UA</i>	<i>Unstable Angina</i>
<i>VCAM-1</i>	<i>Vascular Cell Adhesion Molecule-1</i>
<i>VEGF</i>	<i>Vascular Endothelial Growth Factor</i>
<i>VSMC</i>	<i>Vascular Smooth Muscle Cell</i>
<i>WHO</i>	<i>World Health Organization</i>
<i>XO</i>	<i>Xanthine Oxidase</i>

ABSTRACT

The study revealed that levels of CypA were significantly higher among studied atherosclerotic CAD patients when compared to the control group ($p<0.01$). Also, patients with zero vessel disease showed significantly higher CyPA levels than control group ($p<0.05$); suggesting the role of this marker in early detection of the atherosclerotic process. Moreover, zero vessel disease patients significantly differed in their CyPA levels compared to 1, 2, and 3 vessel disease patients; ($p<0.05$).

On the other hand, the differentiation between more advanced conditions of the CAD, wasn't revealed in our study. There was no significant difference in the CyPA levels among the patients' groups starting from 1 vessel disease till the 3 vessel disease.

Keywords: Sodium Dodecyl Sulphate - Vascular Smooth Muscle Cell - Systolic Blood Pressure

INTRODUCTION

Coronary artery disease is a complex chronic inflammatory disease, characterized by remodeling and narrowing of the coronary arteries supplying oxygen to the heart. It can have various clinical manifestations, including stable angina, acute coronary syndrome, and sudden cardiac death (*DeGoma et al., 2012*). It is the leading cause of death worldwide being responsible for approximately one-third of all deaths in individuals older than 35 years (*Hanson et al., 2013*).

Coronary Artery Disease has a complex etio-pathogenesis and a multi-factorial origin related to environmental factors, such as diet, smoking, and physical activity. However, genetic factors have been claimed to modulate risk of the disease (*Sayols-Baixeras et al., 2014*). Ideally, recognizing those at risk for CAD would help identify such individuals and decrease the incidence of this ominous presentation (*Ibrahim et al., 2012*).

It has been reported that the plasma levels of high-sensitivity C-reactive protein (hs-CRP), brain natriuretic peptide (BNP), D-dimer, and fibrinogen can predict the occurrence of cardiovascular events and progression. However, the plasma levels of these biomarkers are increased in inflammatory diseases, in general, in addition to arteriosclerotic diseases. Thus, the search for a useful biomarker that can effectively predict the risk of future progression to more serious cardiovascular events still remains to be developed (*Ohtsuki et al., 2017*).

Scoring system that predicts the risk of death and MI “GRACE” score (Global Registry of Acute Coronary Events) has been established. The components of the GRACE risk score (ranging from 2 to 372) are age, heart rate, systolic blood pressure, Killip class (classification of heart failure), cardiac arrest at admission, serum creatinine, ST-segment deviation and cardiac biomarker status. According to this score, patients can be grouped into 3 tertiles of death risk; low, intermediate and high (*Khalil et al., 2009*).

Cyclophilin A (CypA) is a protein that is secreted from vascular smooth muscle cells in response to reactive oxygen species (*Taguchi et al., 2013*). It has been claimed that CypA plays a role in the pathogenesis of various cardiovascular diseases such as vascular stenosis. Moreover, it is suggested that CypA plays a role in later stages of atherosclerosis and plaque rupture. However, little information has addressed the potential relationship between CypA and severity in patients with CAD (*Satoh et al., 2013*).

Therefore, researches are designed to investigate the relation between serum CypA concentration and the coronary complex stenosis morphology in patients with CAD (*Yan et al., 2012*).

AIM OF THE WORK

The present study aims to assess severity of CAD and predict future cardiovascular events through:

- A. Correlating levels of serum CyPA with coronary angiography results.
- B. Correlating levels of serum CyPA with GRACE score.